Structure Therapeutics (GPCR)

• Market cap: $1.17B
• 1 day: -4.39%
• 5 days: -11.27%
• 1 month: -15.96%
• 3 months: -34.46%
• 6 months: -49.85%
• Year to date: -27.35%
• 1 year: -39.59%
• 5 years: -21.23%
• 10 years: -21.23%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.

Employees: 163

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

63% more call options, than puts

Call options by funds: $28.1M | Put options by funds: $17.3M

24% more repeat investments, than reductions

Existing positions increased: 63 | Existing positions reduced: 51

22% more first-time investments, than exits

New positions opened: 28 | Existing positions closed: 23

2% more funds holding

Funds holding: 160 [Q3] → 163 (+3) [Q4]

0.59% less ownership

Funds ownership: 35.89% [Q3] → 35.3% (-0.59%) [Q4]

29% less funds holding in top 10

Funds holding in top 10: 7 [Q3] → 5 (-2) [Q4]

39% less capital invested

Capital invested by funds: $2.7B [Q3] → $1.64B (-$1.05B) [Q4]

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $50 144% upside
• Avg. target: $77 276% upside
• High target: $91 344% upside

4 analyst ratings

• positive: 4 100%
• neutral: 0 0%
• negative: 0 0%

Citizens Capital Markets Jonathan Wolleben 31% 1-year accuracy 23 / 75 met price target	325% upside $87	Market Outperform Maintained	28 Feb 2025
Stifel Annabel Samimy 40% 1-year accuracy 4 / 10 met price target	144% upside $50	Buy Initiated	8 Jan 2025
HC Wainwright & Co. Andrew Fein 31% 1-year accuracy 108 / 352 met price target	291% upside $80	Buy Reiterated	20 Dec 2024
JMP Securities Jonathan Wolleben 31% 1-year accuracy 23 / 75 met price target	344% upside $91	Market Outperform Reiterated	18 Dec 2024